Why are Medicare and Medicaid shown separately instead of combined?

They come from two different CMS data sources with no shared claim identifier, so they can't be reconciled into one number without double-counting or guessing. Every table and chart on this page keeps them fully separate.

Why is there no private/commercial revenue figure?

Private and commercial payer data comes from Transparency in Coverage files, which only publish negotiated rates — not claims or utilization volume. Without a volume figure, no revenue number can be computed for any provider from that data.

What does "Rank" mean in the Competitive Analysis & Benchmarks tables?

For a given CPT/HCPCS code, it's this provider's position by claims volume among all providers billing that same code at that geography level (State, National, or Colorado for Medicaid) — rank 1 means the highest claims volume for that code.

Why is the Medicaid comparison limited to Colorado only?

Medicaid is administered per-state with no single national fee schedule, so a state or national comparison the way Medicare has one isn't available. Colorado (this provider's own state) is the only grouping that's conceptually meaningful.

Why are the numbers rounded to the nearest 10?

To avoid implying more precision than the underlying data supports at a single-provider level. Ratios are kept precise since they're a relative comparison, not a volume or dollar figure.

How current is this data?

The Medicare and Medicaid tables are both single current snapshots, not refreshed on a recurring schedule yet.

Matthew Manry (NPI 1366735243)

Field	Value
Entity Type	Individual
Organization	Matthew Manry
Address	1400 Dry Creek Dr
City	Longmont
State	CO
ZIP	80503
Taxonomy	Retina Specialist (Ophthalmology) Physician
NPI Enumerated	May 25, 2011

Payer Source	Total Paid
Medicare	$1.6M
Medicaid	$0

Key Findings

This provider is a retina-focused ophthalmology practice that generates the majority of its Medicare revenue from intravitreal biologic injections and associated clinic visits. The top revenue-driving code is J2777 (faricimab) with 22K claims and $636.8K revenue (40.8% of the provider's Medicare revenue), followed by J0178 (aflibercept) with 600 claims and $408K revenue (26.2%), and 67028 (intravitreal injection) with 902 claims and $91.1K revenue (5.8%). These code choices and volumes are consistent with a medical-retina, injection-centered ambulatory practice rather than a predominantly surgical or hospital-based operation.

Revenue concentration is high: the precomputed top-3 Medicare codes account for 72.8% of the provider's total Medicare revenue, indicating material dependence on a small set of high-cost biologic drugs. Given the overall Medicare revenue of $1.6M, changes in utilization, reimbursement, or drug mix for J2777 and J0178 could meaningfully affect topline Medicare income for this provider.

Payer mix is effectively single-payer at present: the provider reports $1.6M in lifetime Medicare revenue and has no Medicaid billing on file, so Medicaid does not appear to be part of the practice's revenue mix. Analysts should treat this profile as Medicare-dominant when modeling payer risk or access impact, and verify whether commercial payers follow a similar utilization pattern.

Competitive standing on the highest-revenue biologic is in the upper-middle of national peers: J2777 ranks #467 of 2039 providers nationally (77th percentile) and is characterized as "typical, unremarkable volume for this code," which supports that the provider participates at a meaningful but not dominant level in faricimab administration. By contrast J0178 ranks #1772 of 3204 (45th percentile; "typical, unremarkable volume"), indicating more modest aflibercept use relative to national peers.

Certain clinic-level E/M and imaging services show above-typical volume, suggesting robust office throughput that supports the injection service-line. Code 99213 (731 claims, $50.4K revenue) and 92250 (605 claims, $18.2K revenue) are both labeled "notably above typical national volume" (99213 at the 97th percentile and 92250 at the 97th percentile), consistent with high visit and retinal photography activity that typically accompanies an injection-driven retina practice.

Surgical retina procedures appear present but limited: codes such as 67042 and 67036 are billed (15 claims each) and generate modest revenue ($13.6K and $10.1K respectively), each described as "typical, unremarkable volume." This pattern indicates the provider performs some posterior-segment surgery but that surgery is a minor contributor to overall Medicare revenue compared with intravitreal biologics.

A few miscellaneous/administrative drug codes (J3590, J3490, J7999) contribute small but noticeable revenue lines (for example J3590 at $74.2K and J3490 at $72.7K) and are characterized as "typical, unremarkable volume," which could reflect occasional billing for unclassified or compounded agents; these lines are secondary to the main biologic codes. Analysts should review these claims if evaluating drug sourcing or coding consistency but treat them as minor relative to the top biologic claims.

Provider tenure is well-established: the NPI was enumerated on 2011-05-25 (approximately 15 years ago), indicating a sustained presence in the market. That tenure, paired with concentrated biologic and high-volume clinic codes, suggests an entrenched outpatient retina practice serving Medicare beneficiaries in Longmont, CO.

Medicare: Complete Services Breakdown

The CPT/HCPCS codes generating the most Medicare revenue for this provider.

22 rows

CPT/HCPCS Code	Description	Claims	Avg Paid	Revenue
J2777	Injection, faricimab‑svoa, 0.1 mg	21,960	$30	$636.8K
J0178	Injection, aflibercept, 1 mg	600	$680	$408K
67028	The provider injects a medication into the vitreous chamber of the eye as an isolated procedure or a separate procedure unrelated to any other procedure being performed on the eye.	900	$100	$91.1K
J3590	Unclassified biologics	30	$2,560	$74.2K
J3490	Unclassified drugs	40	$1,770	$72.7K
99213	The provider sees an established patient for an office visit or other outpatient visit involving evaluation and management. The visit involves a low level of medical decision making, and/or the…	730	$70	$50.4K
J2781	Injection, pegcetacoplan, intravitreal, 1 mg	390	$120	$46.8K
92134	The provider performs computerized diagnostic imaging of the retina in the posterior segment (back part) of the eye, interprets the data, and provides a report. The service may be on one or both eyes.	1,180	$30	$36.6K
92014	An ophthalmologist sees an established patient for a comprehensive level eye examination. Generally, a patient is considered to be "established" if the same physician, or any physician in the group…	380	$90	$34.6K
99214	The provider sees an established patient for an office visit or other outpatient visit involving evaluation and management. The visit involves a moderate level of medical decision making, and/or the…	230	$100	$22.6K

Showing 1–10 of 22

Medicare: Competitive Analysis & Benchmarks

How this provider's Medicare billing volume and revenue compare to other providers nationally and within its state, across 22 CPT/HCPCS codes.

View: State1 / 2

Claims Volume vs. Colorado Distribution

Matthew Manry — 2 of 22 codes billed far more than typical (above p95)

p5–p95 (all providers)p25–p75MedianThis providerOutlier

Rank Distribution — Colorado

Full comparison — all codes billed, vs. state median

22 rows

CPT/HCPCS Code	Rank	Provider Count	Median Claims	Avg Paid	Average Revenue
J0178	32	60	740	$690	$618.3K
J2777	8	40	8,910	$30	$456.1K
J3590	2	10	20	$2,200	$94.6K
J2781	9	10	470	$120	$79.4K
67028	33	80	670	$100	$73.3K
67036	19	30	20	$1,100	$37.3K
67042	22	30	20	$1,140	$29.6K
J3490	43	60	50	$290	$23.1K
J7999	15	50	230	$70	$21.5K
66821	171	180	40	$240	$15.5K

Showing 1–10 of 22

Related Providers

Other providers that share a Tax Identification Number (TIN) with Matthew Manry, ranked by combined Medicare and Medicaid revenue.

Provider	State	Taxonomy	Medicare Revenue	Medicaid Revenue
University Of Cincinnati Physicians Company, LLC	OH	Family Medicine Physician	$0	$65.2M
Columbus Radiology Corp	OH	Diagnostic Radiology Physician	$0	$49.9M
West Chester Hospital LLC	OH	General Acute Care Hospital	$0	$19.5M
Kettering Independent Medical Group Inc	OH	Orthopaedic Surgery Physician	$0	$8.4M
James Osher	OH	Ophthalmology Physician	$3.7M	$0
Kendall Wannamaker	NC	Ophthalmology Physician	$2.7M	$0
Hang Pham	OH	Ophthalmology Physician	$2.6M	$0
Robert Sisk	OH	Ophthalmology Physician	$2.5M	$0
Lucas Lindsell	OH	Ophthalmology Physician	$2.4M	$0
Elisha Tilton	CO	Ophthalmology Physician	$1.9M	$0

Nearby Providers

Other providers in the same ZIP code as Matthew Manry, ranked by combined Medicare and Medicaid revenue.

Provider	State	Taxonomy	Medicare Revenue	Medicaid Revenue
Kirk Mitchell	CO	Geriatric Medicine (Internal Medicine) Physician	$27.1M	$1M
Advanced Vision Surgery Center LLC	CO	Ambulatory Surgical Clinic/Center	$1.8M	$0
Justin Kanoff	CO	Retina Specialist (Ophthalmology) Physician	$1.7M	$0
Carl Noble	CO	Retina Specialist (Ophthalmology) Physician	$1.7M	$0
Micah Rothstein	CO	Glaucoma Specialist (Ophthalmology) Physician	$283.4K	$0
Anjali Sheth	CO	Glaucoma Specialist (Ophthalmology) Physician	$234K	$0
Front Range Orthopedic Surgery Center LLC	CO	Ambulatory Surgical Clinic/Center	$190.1K	$0
William Cooney	CO	Sports Medicine (Orthopaedic Surgery) Physician	$184.2K	$0
Timothy Pater	CO	Orthopaedic Hand Surgery Physician	$183.1K	$0
Mansi Parikh	CO	Glaucoma Specialist (Ophthalmology) Physician	$167.1K	$0

Matthew Manry — Billing Profile & Reimbursement Data

Sign up for Matthew Manry — Billing Profile & Reimbursement Data policy alerts

Matthew Manry — Billing Profile & Reimbursement Data

Sign up for Matthew Manry — Billing Profile & Reimbursement Data policy alerts

Key Findings

Medicare: Total Revenue Breakdown by CPT/HCPCS Code

Medicare: Complete Services Breakdown

Medicare: Competitive Analysis & Benchmarks

Related Providers

Nearby Providers

Frequently Asked Questions

References